PARP 抑制剂在前列腺癌治疗中的重要性

参考文献：

[1] Castro E, et al. J Clin Oncol. 2019 Feb 20;37(6):490-503.

[2] Zhang Z, et al. Front Endocrinol (Lausanne). 2023 Apr 21;14:1164067.

[3] 叶定伟，等.《2023 CSCO前列腺癌诊疗指南》.

[4] NCCN Clinical Practice Guidelines in Oncology：Prostate Cancer（2024.V4）.

[5] Mateo J, et al. J Clin Oncol. 2024;42(5):571-583.

[6] Abida W et al. Eur Urol. 2023 Sep;84(3):321-330.

[7] Fizazi K, et al. N Engl J Med. 2023;388(8):719-732.

[8] Matthew R Smith, et al.Lancet Oncol. 2022 Mar;23(3):362-373

[9] Johann S de Bono,et al. Lancet Oncol. 2021 Sep;22(9):1250-1264.

[10]Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency. NCT03712930. https://clinicaltrials.gov/study/NCT03712930?term=NCT03712930&rank=1